Risk factors of acute renal impairment after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy

References

• Sugarbaker PH. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of gastrointestinal cancers with peritoneal metastases: progress toward a new standard of care. Cancer Treat Rev. 2016;48:42–49.
   PubMed Web of Science ®Google Scholar
• Wang TY, Chen CY, Lu CH, et al. Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for peritoneal malignancy: preliminary results of a multi-disciplinary teamwork model in Asia. Int J Hyperthermia. 2018;34(3):328–335.
   PubMed Web of Science ®Google Scholar
• Arjona-Sanchez A, Cadenas-Febres A, Cabrera-Bermon J, et al. Assessment of RIFLE and AKIN criteria to define acute renal dysfunction for HIPEC procedures for ovarian and non ovarian peritoneal malignances. Eur J Surg Oncol. 2016;42(6):869–876.
   PubMed Web of Science ®Google Scholar
• Sin EI, Chia CS, Tan GHC, et al. Acute kidney injury in ovarian cancer patients undergoing cytoreductive surgery and hyperthermic intra-peritoneal chemotherapy. Int J Hyperthermia. 2017;33(6):690–695.
   PubMed Web of Science ®Google Scholar
• Ye J, Ren Y, Wei Z, et al. Nephrotoxicity and long-term survival investigations for patients with peritoneal carcinomatosis using hyperthermic intraperitoneal chemotherapy with cisplatin: a retrospective cohort study. Surg Oncol. 2018;27(3):456–461.
   PubMed Web of Science ®Google Scholar
• Hakeam HA, Breakiet M, Azzam A, et al. The incidence of cisplatin nephrotoxicity post hyperthermic intraperitoneal chemotherapy (HIPEC) and cytoreductive surgery. Ren Fail. 2014;36(10):1486–1491.
   PubMed Web of Science ®Google Scholar
• Dagel T, Misirlioglu S, Tanju S, et al. Hyperthermic intraperitonal chemotherapy is an independent risk factor for development of acute kidney injury. J Buon. 2018;23(5):1528–1533.
   PubMed Web of Science ®Google Scholar
• Turaga K, Levine E, Barone R, et al. Consensus guidelines from The American Society of Peritoneal Surface Malignancies on standardizing the delivery of hyperthermic intraperitoneal chemotherapy (HIPEC) in colorectal cancer patients in the United States. Ann Surg Oncol. 2014;21(5):1501–1505.
   PubMed Web of Science ®Google Scholar
• Spiliotis J, Halkia E, Lianos E, et al. Cytoreductive surgery and HIPEC in recurrent epithelial ovarian cancer: a prospective randomized phase III study. Ann Surg Oncol. 2015;22(5):1570–1575.
   PubMed Web of Science ®Google Scholar
• van Driel WJ, Koole SN, Sikorska K, et al. Hyperthermic intraperitoneal chemotherapy in ovarian cancer. N Engl J Med. 2018;378(3):230–240.
   PubMed Web of Science ®Google Scholar
• Roviello F, Caruso S, Neri A, et al. Treatment and prevention of peritoneal carcinomatosis from gastric cancer by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: overview and rationale. Eur J Surg Oncol. 2013;39(12):1309–1316.
   PubMed Web of Science ®Google Scholar
• Rueth NM, Murray SE, Huddleston SJ, et al. Severe electrolyte disturbances after hyperthermic intraperitoneal chemotherapy: oxaliplatin versus mitomycin C. Ann Surg Oncol. 2011;18(1):174–180.
   PubMed Web of Science ®Google Scholar
• De Somer F, Ceelen W, Delanghe J, et al. Severe hyponatremia, hyperglycemia, and hyperlactatemia are associated with intraoperative hyperthermic intraperitoneal chemoperfusion with oxaliplatin. Perit Dial Int. 2008;28(1):61–66.
   PubMed Web of Science ®Google Scholar
• Lee VW, Harris DC. Adriamycin nephropathy: a model of focal segmental glomerulosclerosis. Nephrology. 2011;16(1):30–38.
   PubMed Web of Science ®Google Scholar
• Miller RP, Tadagavadi RK, Ramesh G, et al. Mechanisms of cisplatin nephrotoxicity. Toxins. 2010;2(11):2490–2518.
   PubMed Web of Science ®Google Scholar
• Cata JP, Zavala AM, Van Meter A, et al. Identification of risk factors associated with postoperative acute kidney injury after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy: a retrospective study. Int J Hyperthermia. 2018;34(5):538–544.
   PubMed Web of Science ®Google Scholar
• Bouhadjari N, Gabato W, Calabrese D, et al. Hyperthermic intraperitoneal chemotherapy with cisplatin: amifostine prevents acute severe renal impairment. Eur J Surg Oncol. 2016;42(2):219–223.
   PubMed Web of Science ®Google Scholar
• Cioppa T, Vaira M, Bing C, et al. Cytoreduction and hyperthermic intraperitoneal chemotherapy in the treatment of peritoneal carcinomatosis from pseudomyxoma peritonei. World J Gastroenterol. 2008;14(44):6817–6823.
   PubMed Web of Science ®Google Scholar
• Yang XJ, Huang CQ, Suo T, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy improves survival of patients with peritoneal carcinomatosis from gastric cancer: final results of a phase III randomized clinical trial. Ann Surg Oncol. 2011;18(6):1575–1581.
   PubMed Web of Science ®Google Scholar
• Holmes CJ. Glucotoxicity in peritoneal dialysis-solutions for the solution!!. Adv Chronic Kidney Dis. 2007;14(3):269–278.
   PubMed Web of Science ®Google Scholar
• Stewart CL, Gleisner A, Halpern A, et al. Implications of hyperthermic intraperitoneal chemotherapy perfusion-related hyperglycemia. Ann Surg Oncol. 2018;25(3):655–659.
   PubMed Web of Science ®Google Scholar
• Torphy RJ, Stewart C, Sharma P, et al. Dextrose-containing carrier solution for hyperthermic intraperitoneal chemotherapy: increased intraoperative hyperglycemia and postoperative complications. Ann Surg Oncol. 2020. doi:10.1245/s10434-020-08330-y
   PubMed Web of Science ®Google Scholar
• Brocker C, Thompson DC, Vasiliou V. The role of hyperosmotic stress in inflammation and disease. Biomol Concepts. 2012;3(4):345–364.
   PubMedGoogle Scholar
• Mendez CE, Der Mesropian PJ, Mathew RO, et al. Hyperglycemia and acute kidney injury during the perioperative period. Curr Diab Rep. 2016;16(1):10.
   PubMed Web of Science ®Google Scholar